Patents by Inventor Ofer Levy

Ofer Levy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110189188
    Abstract: Provided is a gp96-derived peptides or homologs or derivatives thereof, pharmaceutical composition including them, a use thereof for therapy and for the manufacture of a medicament, a method of treating a wide range of conditions, disorders and diseases therewith, nucleotide sequences encoding them, antibodies directed to epitopes thereof and fusion proteins including them.
    Type: Application
    Filed: March 12, 2009
    Publication date: August 4, 2011
    Applicant: COMPUGEN LTD.
    Inventors: Yossef Kliger, Ofer Levy, Itamar Borukhov, Anat Amir, Anat Oren
  • Patent number: 7921280
    Abstract: In one embodiment, the present invention includes a retirement unit to receive and retire executed instructions. The retirement unit may include a first array to receive information at allocation and a second array to receive information after execution. The retirement unit may further include logic to calculate an event associated with an executed instruction if information associated with the executed instruction is stored in an on-demand portion of at least one of arrays. Other embodiments are described and claimed.
    Type: Grant
    Filed: June 27, 2008
    Date of Patent: April 5, 2011
    Assignee: Intel Corporation
    Inventors: Zeev Sperber, Rafi Marom, Ofer Levy
  • Publication number: 20110052501
    Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against KIAA0746, CD20 or CD55 antigens, which are differentially expressed in cancer and in specific blood cells, and diagnostic and therapeutic usages. This invention further relates to the discovery of extracellular domains of KIAA0746 and its variants, CD20 and its variants, CD55 and its variants, which are suitable targets for immunotherapy, cancer therapy, treatment of inflammatory, allergic and autoimmune disorders, and drug development.
    Type: Application
    Filed: February 1, 2009
    Publication date: March 3, 2011
    Inventors: Liat Dassa, Galit Rotman, Eve Montia, Avi Yeshah Rosenberg, Anat Cohen-Dayag, Amir Toporik, Zurit Levine, Shira Walach, Shirley Sameach-Greenwald, Yaron Kinar, Ofer Levy, Sergey Nemzar
  • Publication number: 20100322938
    Abstract: Clusterin-derived peptides or homologues or derivatives thereof, pharmaceutical compositions including the same, methods of manufacturing the peptides, homologues, derivatives thereof and compositions including the same, and methods of treating conditions including administering the peptides, homologues, derivatives thereof and compositions including the same, are provided.
    Type: Application
    Filed: January 22, 2009
    Publication date: December 23, 2010
    Applicant: COMPUGEN LTD.
    Inventors: Yossef Kliger, Ofer Levy, Itamar Borukhov, Assaf Wool, Ehud Schreiber, Anat Amir, Zurit Levine, Zohar Tiran, Anat Oren, Amir Toporik
  • Publication number: 20090327663
    Abstract: In one embodiment, the present invention includes a retirement unit to receive and retire executed instructions. The retirement unit may include a first array to receive information at allocation and a second array to receive information after execution. The retirement unit may further include logic to calculate an event associated with an executed instruction if information associated with the executed instruction is stored in an on-demand portion of at least one of arrays. Other embodiments are described and claimed.
    Type: Application
    Filed: June 27, 2008
    Publication date: December 31, 2009
    Inventors: Zeev Sperber, Rafi Marom, Ofer Levy
  • Publication number: 20080193468
    Abstract: The present invention is based on the surprising discovery that agonists of TLR8 are uniquely efficacious in enhancing (e.g. inducing) the immune response of newborns. Thus, agonists of TLR8 serve as both vaccine adjuvants and as adjunctive therapies for acute infection in newborns, preferably the agonist is a TLR8-selective agonist. The immune response induced, or enhanced, in the neonatal host can be, for example, a cytokine immune response and/or a humoral immune response (e.g., antigen-specific).
    Type: Application
    Filed: September 8, 2005
    Publication date: August 14, 2008
    Applicants: CHILDREN'S MEDICAL CENTER CORPORATION, 3M INNOVATIVE PROPERTIES COMPANY
    Inventors: Ofer Levy, Michael Wessels, Richard Miller, Mark Tomai
  • Publication number: 20060252688
    Abstract: New therapeutic uses for BPI protein products that involve treatment of subjects with a BPI deficiency condition, including selective BPI deficiency, and newborns, including BPI-deficient newborns.
    Type: Application
    Filed: May 1, 2006
    Publication date: November 9, 2006
    Inventor: Ofer Levy
  • Patent number: 7041644
    Abstract: New therapeutic uses for BPI protein products that involve treatment of subjects with a BPI deficiency condition, including selective BPI deficiency, and newborns, including BPI-deficient newborns.
    Type: Grant
    Filed: April 23, 2002
    Date of Patent: May 9, 2006
    Assignee: XOMA Technology
    Inventor: Ofer Levy
  • Publication number: 20030027762
    Abstract: New therapeutic uses for BPI protein products that involve treatment of subjects with a BPI deficiency condition, including selective BPI deficiency, and newborns, including BPI-deficient newborns.
    Type: Application
    Filed: April 23, 2002
    Publication date: February 6, 2003
    Applicant: XOMA Technology Ltd.
    Inventor: Ofer Levy
  • Patent number: 6376465
    Abstract: New therapeutic uses for BPI protein products that involve treatment of subjects with a BPI deficiency condition, including selective BPI deficiency, and newborns, including BPI-deficient newborns.
    Type: Grant
    Filed: April 3, 2000
    Date of Patent: April 23, 2002
    Assignee: XOMA Technology Ltd.,
    Inventor: Ofer Levy
  • Patent number: 6299629
    Abstract: An automatic tourniquet system (10) including variable pressure cuff apparatus (60) for applying a variable pressure to a limb or artery of a patient in order to occlude blood flow thereat and control apparatus (40) for determining the operative pressure of the variable pressure cuff (20) apparatus and including apparatus for estimating the minimum effective cuff pressure required for complete occlusion.
    Type: Grant
    Filed: September 24, 1998
    Date of Patent: October 9, 2001
    Assignees: FMS-Future Medical System, S.A., Future Medical Systems, S.A.
    Inventors: Frank Vincenz Jonas Gruenfeld, Alexander Opatowsky, Joel Engel, Yehouda David, Ofer Levy
  • Patent number: 6153584
    Abstract: New therapeutic uses for BPI protein products that involve treatment of subjects with a BPI deficiency condition, including selective BPI deficiency, and newborns, particularly BPI-deficient newborns.
    Type: Grant
    Filed: April 1, 1999
    Date of Patent: November 28, 2000
    Inventor: Ofer Levy
  • Patent number: 5842996
    Abstract: An automatic tourniquet system (10) including variable pressure cuff apparatus (60) for applying a variable pressure to a limb or artery of a patient in order to occlude blood flow thereat and control apparatus (40) for determining the operative pressure of the variable pressure cuff (20) apparatus and including apparatus for estimating the minimum effective cuff pressure required for complete occlusion.
    Type: Grant
    Filed: January 22, 1996
    Date of Patent: December 1, 1998
    Assignees: FMS-Future Medical System, S.A., Future Medical Systems, S.A.
    Inventors: Frank Vincenz Jonas Gruenfeld, Alexander Opatowsky, Joel Engel, Yehouda David, Ofer Levy